Clinical Trial Update: StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating StrataGraft skin tissue as an alternative to autografting for full-thickness skin defects was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burns
• Skin Wound
• Trauma-related Wounds

Drugs mentioned

• StrataGraft

Snippet

Sponsor: Stratatech, a Mallinckrodt Company | Conditions: Trauma-related Wound, Burns | Phase 2 | Status: TERMINATED | Results posted: 2021-08-03